An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination with Itraconazole Capsules in Healthy Adult Female and Male Participants

2023-509002-30-00 Protocol D7860C00004 Human pharmacology (Phase I) - Other Ended

Start 25 Jun 2024 · End 5 Oct 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol D7860C00004

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 16
Countries 1
Sites 1

Chronic obstructive pulmonary disease

Key facts

Sponsor
AstraZeneca AB
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20], Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
25 Jun 2024 → 5 Oct 2024
Decision date (initial)
2024-06-24
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic obstructive pulmonary disease

VersionLevelCodeTermSystem organ class
26.1 PT 10009033 Chronic obstructive pulmonary disease 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
-
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Public contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 16 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
PAREXEL International GmbH
1: Parexel Early Phase Unit Berlin, Klinikum Westend Haus 31, Spandauer Damm 130, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-06-25 2024-10-05 2024-06-25 2024-09-03

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-29 Germany Acceptable
2024-06-24
2024-06-24